logo-loader
viewQ BioMed Inc

Q BioMed CEO sees significant capital funding for next 3 years

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive announced that its technology partner, Mannin Research Inc, has received a $7.5 million grant from the German state of Saxony to fund the development of its glaucoma therapies.

Corin talked about how the two partners plan to accelerate the pre-clinical efforts of its two approaches to prevent glaucoma.

Quick facts: Q BioMed Inc

Price: 0.43 USD

OTCMKTS:QBIO
Market: OTCMKTS
Market Cap: $7.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc named herein, including the promotion by the Company of Q BioMed Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Q BioMed selects 'the perfect partner' to distribute its...

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive the company has entered into an exclusive distribution agreement for its non-opioid, FDA-approved drug Strontium-89, which is aimed to control bone pain caused by cancer. Corin says the company has chosen 'the perfect partner' in...

on 10/04/2019

2 min read